IP Group (LON:IPO) Releases Earnings Results

IP Group (LON:IPO) announced its quarterly earnings data on Tuesday. The company reported GBX 3.53 EPS for the quarter, Digital Look Earnings reports. IP Group had a return on equity of 14.25% and a net margin of 321.64%.

Here are the key takeaways from IP Group’s conference call:

• NAV per share rose 3.2% to 114p at June 30 and approximately 117p by September 11, while gross cash reached about £239 million. Portfolio companies also raised more than £500 million from third parties, providing external validation of their progress.
• Pfizer’s obesity programs continued to de-risk, with the royalty asset’s carrying value increasing by £27 million to roughly £153 million after the amylin combination entered Phase IIb. Berobenatide Phase III recruitment is reportedly close to completion, supporting a potential 2028 launch, although clinical, regulatory and commercial risks remain.
• Cash realizations were strong at £69 million in the first half and approximately £86 million year to date, taking cumulative proceeds since the start of 2025 to £154 million. Management remains confident in reaching its £250 million realization target by the end of 2027.
• Oxford Nanopore reported 12% constant-currency revenue growth, a 400-basis-point gross-margin improvement and an adjusted EBITDA loss that more than halved. It remains on track for EBIT break-even in 2027 and positive free cash flow in 2028, supported by a new cross-licensing agreement with $35 million of committed revenue plus royalties.
• Management acknowledged that the shares continue to trade at roughly a 40% discount to NAV and said reducing the gap will require sustained NAV growth, more realizations and shareholder-focused capital allocation. Around £50 million is available for potential shareholder returns, but the timing and form of any action have not been decided.

IP Group Stock Up 0.0%

Shares of IPO opened at GBX 68.82 on Thursday. The stock has a market capitalization of £608.01 million, a P/E ratio of 9.69 and a beta of 1.27. IP Group has a twelve month low of GBX 48 and a twelve month high of GBX 75. The firm has a fifty day simple moving average of GBX 67.85 and a two-hundred day simple moving average of GBX 63.09.

Insider Buying and Selling at IP Group

In other news, insider David Baynes acquired 26,368 shares of the stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of GBX 68 per share, with a total value of £17,930.24. Also, insider Michael Queen bought 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was acquired at an average cost of GBX 66 per share, for a total transaction of £132,000. Over the last quarter, insiders have bought 271,368 shares of company stock worth $18,053,024. 1.57% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IPO. Berenberg Bank restated a “buy” rating and set a GBX 119 price target on shares of IP Group in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 110 target price on shares of IP Group in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of GBX 114.50.

IP Group Company Profile

IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK’s largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach.